drugset / Trial / NCT03120000
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL).
Timeline
- Start
- 2017-12
- Primary completion
- 2018-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimiralisib | Small molecule | 60 mg | Oral |
| Subject | Bimiralisib | Small molecule | 80 mg | Oral |